ARCHIVES

Bertagnolli: Why Brigham Stopped Making Morcellation Available Outside Of A Registry Trial

This article is from The Cancer Letter archive.

Vol. 40 No. 27 | July 4, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Approves Rituxan For NHL With CHOP Therapy

February 24, 2006

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

NEJM Sanctioned For Giving CME Credit For Controversial Lung Screening Paper; ACCME Demanded Corrective Action

January 9, 2009

NCI Internal Debate Ends With Move of Biometry Branch, Including SEER, From DCCP To DRCCA

September 23, 1983

NCI to Close Clinical Branch at Frederick, Move Patients, Protocols To Bethesda

May 17, 1996

Trading In Stock Of U.S. Bioscience Halted, Newsletter Report Cited

October 9, 1992